Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
Curtis A. Lachowiez(Oregon Health & Science University), Daniel A. Pollyea(University of Colorado Denver), Jenny O’Nions(University College London Hospitals NHS Foundation Trust), D. Peters(University of North Carolina at Chapel Hill), Ronan Swords(University of Miami), Richard Dillon(King's College London), Jennifer N. Saultz(Oregon Health & Science University), Jad Othman(King's College London), Jeffrey Tyner(Washington University in St. Louis), Vishvaas I Ravikumar(Oregon Health & Science University), Christine M. McMahon(Albert Einstein College of Medicine), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Rachel C. Cook(Oregon Health & Science University)
Cited by 30
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
|Cancer Cell|2018|565